Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
TURKU, FI / ACCESS Newswire / December 22, 2025 / Faron Pharmaceuticals Ltd. (AIM:ARN, First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company, today announces the finalization of agreements to initiate the BLAZE trial, a new investigator-initiated trial (IIT) in the UK. The trial is conducted via a strategic collaboration with The Institute of Cancer Research, London (ICR), operating in partnership with The Royal Marsden NHS Foundation Trust. This collaboration leverages the world-class expertise of these globally recognized leaders in cancer research, innovation, and treatment. The Phase I/II BLAZE trial will investigate Faron's lead asset, bexmarilimab , in combination with the anti-PD-1 checkpoint inhibitor, zimberelimab provided by Gilead Sciences, for patients with metastatic non-small cell lung cancer (NSCLC) and melanoma who have developed resistance to prior anti-PD-1-based immunotherapy and progressed within three months of the last anti-PD-1 t
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Biopharma climbs higher as 9 drugmakers ink ‘pandering' drug price deals with Trump [Yahoo! Finance]Yahoo! Finance
- 3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital HerpesBusiness Wire
- Why Gilead Sciences (GILD) Stock Is Up Today [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- GILD's page on the SEC website